Related Experiment Video

Updated: Jul 17, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

New treatment options for acute coronary syndromes

Charles L Campbell1

  • 1University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T. Wethington Bldg, Lexington, KY 40536-0200, USA. clcampbell@uky.edu

The American Journal of Managed Care
|January 6, 2007
PubMed

Insights

Novel antithrombotic therapies, like fondaparinux sodium, offer advantages over traditional unfractionated heparin for acute coronary syndromes (ACS). These newer agents aim to improve treatment efficacy and patient monitoring for cardiovascular disease management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis Research

Background:

  • Atherosclerotic coronary artery disease is a leading global cause of mortality.
  • Current treatments for acute coronary syndromes (ACS) include unfractionated heparin, which has limitations such as intravenous administration and the need for frequent monitoring.
  • Development of newer antithrombotic agents aims to overcome these limitations.

Purpose of the Study:

  • To review novel antithrombotic therapies for the management of acute coronary syndromes (ACS).
  • To highlight fondaparinux sodium as a synthetic inhibitor of clotting factor Xa.
  • To discuss the advantages of newer agents over traditional therapies.

Main Methods:

  • Literature review of clinical trials and therapeutic strategies.
  • Focus on pharmacological mechanisms of novel antithrombotic agents.
  • Comparative analysis of existing and emerging treatments for ACS.

Main Results:

  • Novel antithrombotic agents are being developed with improved pharmacokinetic profiles.
  • Fondaparinux sodium demonstrates potential as an effective alternative to unfractionated heparin.
  • Newer agents may reduce the need for intensive patient monitoring.

Conclusions:

  • Novel antithrombotic therapies represent a significant advancement in ACS management.
  • Fondaparinux sodium is a promising synthetic factor Xa inhibitor for ACS.
  • Further research and clinical adoption of these agents could improve patient outcomes.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...